Greenwich LifeSciences, Inc.
Veridion Score
Composite trend over time
Why is GLSI moving today?
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GLSI.
GLSI insider activity
Greenwich LifeSciences, Inc.
No multi-insider buying cluster in the last 90 days
Net buying: $489K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | 2026-01-13 | Patel Snehal | Insider | buy | $29.83 | 1,800 | 5,604,102 | $54K | SEC Form 4 |
| 2026-01-14 | 2026-01-12 | Patel Snehal | Insider | buy | $27.54 | 2,900 | 5,602,302 | $80K | SEC Form 4 |
| 2026-01-05 | 2025-12-31 | Patel Snehal | Insider | buy | $21.36 | 4,300 | 5,599,402 | $92K | SEC Form 4 |
| 2026-01-02 | 2025-12-30 | Patel Snehal | Insider | buy | $21.73 | 2,900 | 5,595,102 | $63K | SEC Form 4 |
| 2025-12-19 | 2025-12-18 | Patel Snehal | Insider | buy | $12.62 | 4,100 | 5,592,202 | $52K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moGLSI contract awards, year to date.
Public federal awards linked to this ticker.
GLSI lobbying filings, year to date.
Registered lobbying filings matched to Greenwich LifeSciences, Inc..